NCT02762487终止不适用
RELIEF Europe Study. A Prospective, Multicenter Study of RefluxManagement With the LINX® System for Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy
Torax Medical Incorporated7 个研究点 分布在 2 个国家目标入组 7 人开始时间: 2015年11月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 7
- 试验地点
- 7
- 主要终点
- Change is GERD-HRQL Score as a measure of efficacy
研究概览
简要总结
The purpose of this study is to evaluate the LINX device in patients who have previously undergone laparoscopic sleeve gastrectomy (LSG) for obesity and have chronic gastroesophageal reflux disease (GERD). The study will monitor safety and changes in reflux symptoms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Laparoscopic sleeve gastrectomy (LSG) for obesity >12 months prior to proposed device implantation date.
- •Patient is a surgical candidate, i.e. is able to undergo general anesthesia and laparoscopic surgery.
- •Documented pathologic esophageal acid exposure by pH monitoring per institution's standard of care (i.e. total distal ambulatory esophageal pH< 4 for ≥ 5.3% (BRAVO) or ≥4.5% (transnasal) or abnormal DeMeester Score (>14.72) within 12 months of proposed implantation date (After Sleeve Gastrectomy).
- •NOTE: SUBJECTS SHALL HAVE DISCONTINUED ALL GERD MEDICATIONS FOR AT LEAST 7 DAYS PRIOR TO TESTING WITH THE EXCEPTION OF ANTACIDS, WHICH MAY BE TAKEN UP UNTIL THE MORNING OF THE VISIT.
- •Chronic GERD symptoms despite maximum medical therapy for the treatment of reflux.
- •Age ≥ 21 years
- •At least 30% loss of excess weight from date of original LSG surgery.
- •Patient is willing and able to cooperate with follow-up examinations.
- •Patient has been informed of the study procedures and the treatment and has signed an informed consent form.
排除标准
- •Suspected or known allergies to titanium, stainless steel, nickel, or ferrous materials.
- •Prior surgery in the area of the gastroesophageal junction (GEJ), including prior hiatal hernia repair.
- •Presence of ˃3 cm hiatal hernia as determined by endoscopy or barium esophagram.
- •Subject had any major complications related to the laparoscopic sleeve gastrectomy that may interfere with, or increase the risks of the LINX procedure (such as, but not limited to, leaks from the gastric remnant and infection at the sleeve gastrectomy).
- •Plans to surgically revise the gastric pouch (either known preoperatively or decided intraoperatively).
- •Currently being treated with another investigational drug or investigational device.
- •Suspected or confirmed esophageal or gastric cancer or prior gastric or esophageal surgery or endoscopic intervention for GERD (with the exception of sleeve gastrectomy).
- •Distal amplitude <35 mmHg or <70% peristaltic sequences.
- •Presence of esophagitis - Grade C or D (LA Classification). BMI >
- •Symptoms of dysphagia more than once per week within the last 3 months.
- •Diagnosed with Scleroderma.
- •Diagnosed with an esophageal motility disorder such as but not limited to achalasia, nutcracker esophagus, or diffuse esophageal spasm or hypertensive LES.
- •Patient has a history of or known esophageal stricture or gross esophageal anatomic abnormalities (Schatzki's ring, obstructive lesions, etc.).
- •Patient has esophageal or gastric varices.
- •Patient has Barrett's esophagus.
- •Patient cannot understand trial requirements or is unable to comply with follow-up schedule.
- •Pregnant or nursing, or plans to become pregnant during the course of the study.
- •Any reason which the Investigator believes may cause the subject to be non-compliant with or unable to meet the protocol requirements.
- •Patient has an electrical implant or metallic, abdominal implants.
研究组 & 干预措施
LINX arm
Experimental
Previous LSG patient will be treated with the LINX device and serve as their own control
干预措施: The LINX® Reflux Management System (Device)
结局指标
主要结局
Change is GERD-HRQL Score as a measure of efficacy
时间窗: Baseline, 6 month visit
Number of participants with serious complications as a measure of safety.
时间窗: 6 month visit
Change is total distal acid exposure as a measure of efficacy.
时间窗: Baseline, 6 month visit
次要结局
未报告次要终点
研究者
研究点 (7)
Loading locations...
相似试验
已完成
不适用
LINX Reflux Management System in Subjects With GERD Who Have Previously Undergone a Laparoscopic Sleeve GastrectomyGERDGastroesophageal Reflux DiseaseNCT02429830Torax Medical Incorporated30
终止
2 期
A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine TumoursNCT02288377Federation Francophone de Cancerologie Digestive53
撤回
不适用
RELIEF Study: Real-world Evaluation of LUTS Interventions and Patient Experience During Follow-upBenign Prostatic HyperplasiaNCT05784558NeoTract, Inc.2,500
已完成
不适用
A clinical study to evaluate the effects of the Linablue tablet on skin functioJPRN-UMIN000035205Soiken Inc.96
已完成
1 期
A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese VolunteersMetabolism and Nutrition DisorderObesityNCT00978393Novo Nordisk A/S49